Northern Trust Corp increased its stake in Aratana Therapeutics, Inc. (NASDAQ:PETX) by 10.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 463,984 shares of the biopharmaceutical company’s stock after buying an additional 43,967 shares during the period. Northern Trust Corp owned 1.22% of Aratana Therapeutics worth $3,355,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. American International Group Inc. increased its stake in Aratana Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares during the period. Janney Montgomery Scott LLC increased its stake in Aratana Therapeutics by 7.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Aratana Therapeutics by 17.9% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares during the period. Ray Gerald L & Associates Ltd. increased its stake in Aratana Therapeutics by 0.8% in the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 200 shares during the period. Finally, ProShare Advisors LLC increased its stake in Aratana Therapeutics by 7.2% in the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 1,709 shares during the period. 73.66% of the stock is currently owned by institutional investors.

Aratana Therapeutics, Inc. (PETX) opened at $7.10 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. Aratana Therapeutics, Inc. has a 12-month low of $4.97 and a 12-month high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The business had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The company’s revenue for the quarter was up 1440.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.38) EPS. research analysts expect that Aratana Therapeutics, Inc. will post -1.03 earnings per share for the current year.

In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $7.00, for a total transaction of $350,000.00. Following the transaction, the insider now owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the transaction, the insider now directly owns 130,994 shares in the company, valued at approximately $818,712.50. The disclosure for this sale can be found here. Insiders have sold a total of 120,000 shares of company stock worth $785,600 in the last three months. Insiders own 5.20% of the company’s stock.

Several research analysts recently commented on PETX shares. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. BidaskClub downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Lake Street Capital cut their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Jefferies Group LLC reissued a “buy” rating and set a $8.00 target price on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Finally, HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research report on Friday, November 17th. They set a “buy” rating and a $10.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Aratana Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.75.

COPYRIGHT VIOLATION NOTICE: “Aratana Therapeutics, Inc. (PETX) Position Lifted by Northern Trust Corp” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/aratana-therapeutics-inc-petx-position-lifted-by-northern-trust-corp/1723216.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.